Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600221 | 0.71 | — | — | |
| SCHEMBL626634 | 0.70 | SLC6A4 (0.39) | SLC6A4SLC6A3ALDH1A1LMNAGSK3B | |
| SCHEMBL15980826 | 0.69 | NPSR1 (0.34) | ALDH1A1KDM4ENPSR1 | |
| SCHEMBL15980807 | 0.69 | LMNA (0.39) | ALDH1A1KDM4ELMNANPSR1 | |
| SCHEMBL13532086 | 0.69 | TAAR1 (0.50) | — | |
| SCHEMBL172640 | 0.69 | CA2 (0.34) | SLC6A4SLC6A3ALDH1A1KDM4ELMNA | |
| SCHEMBL621798 | 0.68 | CES2 (0.35) | SLC6A4SLC6A3ALDH1A1LMNAGSK3B | |
| SCHEMBL3871715 | 0.68 | ALDH1A1 (0.35) | SLC6A4SLC6A3ALDH1A1LMNANPSR1 | |
| SCHEMBL2526951 | 0.68 | CA2 (0.42) | SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL13995989 | 0.68 | ALDH1A1 (0.38) | SLC6A4SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354406-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120035164-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-02-09 | — | — | US | disclosed |
| US-8063071-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-06-04 | — | — | US | disclosed |
| EP-1896014-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005534-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035164-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | SLC6A4 4402/4885SLC6A3 4768/4885ALDH1A1 2634/4885 |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | SLC6A4 4402/4885SLC6A3 4768/4885ALDH1A1 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.